Affiliation: St. Michael's Hospital
- A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesP W O'Connor
University of Toronto, Ontario, Canada
Neurology 66:894-900. 2006..In this randomized, double-blind, placebo-controlled Phase II study, the authors examined the safety and efficacy of oral teriflunomide in multiple sclerosis (MS) with relapses...
- Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension studyP O'CONNOR
St Michael s Hospital, Toronto, ON, Canada
Neurology 72:73-9. 2009..To report the results of a 24-month extension of a phase II trial assessing the efficacy, safety, and tolerability of the once-daily oral sphingosine-1-phosphate receptor modulator, fingolimod (FTY720), in relapsing multiple sclerosis (MS)...
- Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS StudyPaul O'Connor
From the Department of Neurology P O, St Michael s Hospital, Toronto, Canada Department of Neurology A G, University of Rochester, NY Departments of Neurology and Biomedicine L K, University Hospital Basel, Switzerland Corinne Goldsmith Dickinson Center for MS at The Icahn School of Medicine at Mount Sinai F L, New York, NY Department of Neurology C P, VU Medical Centre, Amsterdam, the Netherlands Mellen Center for Multiple Sclerosis Treatment and Research R A R, Cleveland Clinic Foundation, OH Infusion Communications K H, Haddam, CT Departments of Safety and Benefit Risk Management L M C and Biostatistics F F, Biogen Idec Inc, Cambridge and Sarepta Therapeutics P D, Cambridge, MA P D, a former employee of Biogen Idec Inc, was at the company during study conduct
Neurology 83:78-86. 2014..Report long-term safety and effectiveness of natalizumab over 240 weeks in the prospective, observational, open-label Safety of TYSABRI Re-dosing and Treatment (STRATA) Study...
- Disease-modifying agents in multiple sclerosisPaul W O'Connor
Multiple Sclerosis Clinic, St Michael s Hospital, Toronto, Canada Electronic address
Handb Clin Neurol 122:465-501. 2014..This chapter will consider the efficacy and safety of both established and investigational agents for the treatment of MS. ..
- The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPSPaul O'Connor
Division of Neurology, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
Clin Ther 25:2865-74. 2003....
- Disease activity return during natalizumab treatment interruption in patients with multiple sclerosisP W O'Connor
St Michael s Hospital, Toronto, Ontario, Canada
Neurology 76:1858-65. 2011....
- 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyPaul O'Connor
St Michael s Hospital, Toronto, Canada
Lancet Neurol 8:889-97. 2009....
- Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteriaP O'CONNOR
St Michael s Hospital, Toronto, ON, Canada
Mult Scler 15:728-34. 2009..0007, P = 0.0405) and patients with at least nine T2 lesions at baseline (P = 0.0044). These data confirm that IM IFNbeta-1a delays conversion to CDMS in patients with CIS...
- Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosisPaul O'Connor
St Michael s Hospital, Division of Neurology, 30 Bond Street, Suite 3 007 Shuter Wing, University of Toronto, Toronto, Ontario, M5B 1W8, Canada
Expert Opin Biol Ther 7:123-36. 2007....
- Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosisPaul O'Connor
Division of Neurology, St Michael s Hospital, 30 Bond Street, Suite 3007S Shuter Wing, Toronto, Ontario, Canada
Mult Scler 11:568-72. 2005..In a six month, phase II clinical trial of patients with relapsing MS, natalizumab significantly reduced the formation of new gadolinium-enhanced (Gd+) lesions and the number of clinical relapses...
- Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effectsP W O'Connor
St Michael s Hospital, Toronto, Ontario, Canada
Neurology 62:2038-43. 2004..Natalizumab (Antegren) is a humanized anti-alpha4-integrin antibody that inhibits the trafficking of leukocytes across endothelium by blocking binding of alpha4beta1-integrin to vascular cell adhesion molecule-1...
- Robust perfusion deficits in cognitively impaired patients with secondary-progressive multiple sclerosisP L Francis
Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
AJNR Am J Neuroradiol 34:62-7. 2013..Cognitive impairment is a common, disabling symptom of MS. We investigated the impact of cerebral perfusion and brain and lesion volumetry on cognitive performance in 45 patients with SPMS by using MR imaging...
- Regional Frontal Perfusion Deficits in Relapsing-Remitting Multiple Sclerosis with Cognitive DeclineR Vitorino
From the Departments of Psychiatry A F, Neurology L L, and Medical Imaging R V, S P H, L Z, R I A, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada Departments of Medicine L L, P O, Psychiatry A F, and Medical Imaging S P H, R I A, University of Toronto, Toronto, Ontario, Canada and Departments of Biomedical Engineering C G C, T J C and Radiology T J C, Northwestern University, Chicago, Illinois
AJNR Am J Neuroradiol . 2016..We sought to localize perfusion distribution differences in patients with relapsing-remitting MS with and without cognitive impairment and healthy controls...
- Cortical Perfusion Alteration in Normal-Appearing Gray Matter Is Most Sensitive to Disease Progression in Relapsing-Remitting Multiple SclerosisS P Hojjat
Medical Imaging S P H, M K, R V, R I A, L Z, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada Medical Imaging S P H, R I A, University of Toronto, Toronto, Ontario, Canada
AJNR Am J Neuroradiol 37:1454-61. 2016..We sought to use bookend perfusion to quantify parameters in healthy controls and normal-appearing and lesional tissue at different relapsing-remitting MS stages...
- Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS studyM S Freedman
Ottawa Hospital General Campus, Ottawa, Ontario, Canada
Mult Scler 11:41-5. 2005..Once weekly interferon beta-1a for multiple sclerosis (OWIMS) demonstrated modest, but significant, magnetic resonance imaging (MRI) benefit of once-weekly (qw) interferon (IFN) beta-1a at 48 weeks, but no significant effect on relapses...
- A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MSM S Freedman
University of Ottawa, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, Ontario, Canada
Neurology 77:1551-60. 2011..To evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis (SPMS) who express human leukocyte antigen (HLA) haplotype DR2 or DR4 (DR2(+) or DR4(+))...
- Randomized trial of oral teriflunomide for relapsing multiple sclerosisPaul O'Connor
University of Toronto, Toronto, ON, Canada
N Engl J Med 365:1293-303. 2011..Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple sclerosis...
- Comparison of Quantitative Cerebral Blood Flow Measurements Performed by Bookend Dynamic Susceptibility Contrast and Arterial Spin-Labeling MRI in Relapsing-Remitting Multiple SclerosisR M D'Ortenzio
University of Toronto R M D, P O C, L L, A F, R I A, Toronto, Ontario, Canada
AJNR Am J Neuroradiol 37:2265-2272. 2016..The noninvasive nature of pseudocontinuous arterial spin-labeling is advantageous over gadolinium-based techniques, but correlation between the techniques is not well-established in the context of MS...
- A rapid ELISA-based serum assay for myelin basic protein in multiple sclerosisA J Chamczuk
Structural Biology and Biochemistry, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada M5G 1X8
J Immunol Methods 262:21-7. 2002..The success of the assay is dependent on the use of heparin, an anionic molecule, which neutralizes the positive charge on the highly cationic MBP...
- Decreased frontal lobe gray matter perfusion in cognitively impaired patients with secondary-progressive multiple sclerosis detected by the bookend techniqueR I Aviv
Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
AJNR Am J Neuroradiol 33:1779-85. 2012..We sought to quantify differences in MR imaging-based bookend-derived cerebral perfusion between cognitively impaired and nonimpaired patients with SPMS...
- Multiple sclerosis fatigue is associated with reduced psychomotor vigilanceD Rotstein
Division of Neurology, Department of Medicine, University of Toronto, Canada
Can J Neurol Sci 39:180-4. 2012..Fatigue is common and disabling in multiple sclerosis, yet its physiologic substrates remain poorly defined. The aim of this study was to determine the relationship between fatigue and an objective measure of alertness in MS patients...
- APOE epsilon4 and the cognitive genetics of multiple sclerosisO Ghaffar
Neuropsychiatry Program, Department of Psychiatry, Sunnybrook Health Sciences Centre, FG08 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada
Neurology 74:1611-8. 2010..The purpose of this study was to determine whether the epsilon4 allele of APOE is associated with cognitive deficits in patients with MS...
- A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosisJ M Burton
Division of Neurology, St Michael s Hospital, Toronto, Canada
Neurology 74:1852-9. 2010..Our aim was to assess the tolerability of high-dose oral vitamin D and its impact on biochemical, immunologic, and clinical outcomes in patients with MS prospectively...
- Diffusion tensor imaging abnormalities in depressed multiple sclerosis patientsA Feinstein
Department of Psychiatry, University of Toronto, Toronto, Canada
Mult Scler 16:189-96. 2010....
- Age at onset of multiple sclerosis may be influenced by place of residence during childhood rather than ancestryJ Kennedy
The Hospital for Sick Children, University of Toronto, Toronto, Ont L5M 4A7, Canada
Neuroepidemiology 26:162-7. 2006....